H2-antagonists in the treatment of colon and breast cancer

Seminars in Cancer Biology

Volumn 10, Issue 1, 2000, Pages 3-10

  Bolton, Elaine ^a   King, Julie ^a   Morris, David L ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

Cell mediated immunity; Histamine; Histamine antagonists; Tumour infiltrating lymphocytes

Indexed keywords

CIMETIDINE; HISTAMINE; HISTAMINE H2 RECEPTOR ANTAGONIST; RANITIDINE;

BREAST CANCER; CANCER GROWTH; CANCER SURVIVAL; CELLULAR IMMUNITY; CLINICAL TRIAL; COLON CANCER; DIGESTIVE SYSTEM CANCER; HISTAMINE BLOOD LEVEL; HUMAN; REVIEW; TUMOR ASSOCIATED LEUKOCYTE;

EID: 0034043052     PISSN: 1044579X     EISSN: None     Source Type: Journal    
DOI: 10.1006/scbi.2000.0301     Document Type: Article

References (48)

1. Adams W J, Lawson J A, Morris D L. Cimetidine inhibits in vivo growth of human colon cancer and reverses histamine stimulated in vitro and in vivo growth. Gut. 35:1994;1632-1636.
2. Adams W J, Lawson J A, Nicholson S E, Cook T A, Morris D L. The growth of carcinogen-induced colon cancer in rats is inhibited by cimetidine. Eur J Surg Oncol. 19:1993;332-335.
3. Adams W J, Morris D L. Short-course cimetidine and survival with colorectal cancer [Letter]. Lancet. 344:1994;1768-1769.
4. Adams W J, Morris D L. Pilot study - cimetidine enhances lymphocyte infiltration of human colorectal carcinoma. Cancer. 80:1997;15-21.
5. Adams W J, Morris D L, Ross W B, Lubowski D Z, King D W, Peters L. Cimetidine preserves non-specific immune function after colonic resection for cancer. Aust N Z J Surg. 64:1994;847-852.
6. Bartholeyns J, Bouclier M. Involvement of histamine in growth of mouse and rat tumors: antitumoral properties of monofluoromethylhistidine, an enzyme-activated irreversible inhibitor of histidine decarboxylase. Cancer Res. 44:1984;639-645.
7. Bowrey P F, King J, Magarey C, Schwartz P, Marr P, Bolton E, Morris D L. Histamine, mast cells and tumour cell proliferation in breast cancer: Does pre-operative cimetidine administration have an effect? Br. J. Cancer. 82:2000;167-170.
8. Burtin C, Noirot C, Paupe J, Scheinmann P. Decreased blood histamine levels in patients with solid malignant tumours. Br J Cancer. 47:1983;367-372.
9. Burtin C, Noirot C, Scheinmann P, Galoppin L, Sabolovic D, Bernard P. Clinical improvement in advanced cancer disease after treatment combining histamine and H2-antihistaminics (ranitidine or cimetidine). Eur J Cancer Clin Oncol. 24:1988;161-167.
10. 2histamine receptors. Br J Cancer. 45:1982;54-60.
11. Burtin C, Schienmann P, Salomon J C, Lespinats G, Frayssinet C, Lebel B, Canu P. Increased tissue histamine in tumour-bearing mice and rats. Br J Cancer. 43:1981;684-688.
12. Carlsson R, Dohlsten M, Sjogren H O. Histamine modulates the production of interferon-g and interleukin-2 by mitogen-activated human mononuclear blood cells. Cell Immunol. 96:1985;104-112.
13. Chanda R, Ganguly A K. Diamineoxidase activity and tissue histamine content of human skin, breast and rectal carcinoma. Cancer Lett. 34:1987;207-212.
14. Cricco G P, Davio C A, Martin G, Engel N, Fitzsimons C P, Bergoc R M, Rivera E S. Histamine as an autocrine growth factor in experimental mammary carcinomas. Agents Actions. 43:1994;17-20.
15. Davio C A, Cricco G P, Bergoc R M, Rivera E S. H1 and H2 histamine receptors in N -nitroso- N -methylurea (NMU)-induced carcinomas with atypical coupling to signal transducers. Biochem Pharmacol. 49:1995;1-6.
16. Dohlsten M, Kalland T, Sjogren H-O, Carlsson R. Histamine inhibits interleukin 1 production by lipopolysaccharide-stimulated human peripheral blood monocytes. Scand J Immunol. 27:1988;527-532.
17. Dwerryhouse S J, L C S, King J, Magarey C, Schwartz P, M D L. Cimetidine does not influence TIL in breast cancer. J Surg Invest. 1999.
18. Finlay I G, Dwerryhouse S J, King J, King D W, Lubowski D Z, Morris D L. The effect of a short preoperative course of cimetidine on the grade of TIL in primary colorectal cancer - a randomised controlled clinical trial. GI. Cancer. 3:1999;121-127.
19. Fischer E R, Paik S M, Rockette H, Jones J, Caplan R, Fisher E R. Prognostic significance of eosinophils and mast cells in rectal cancer. Hum Pathol. 20:1989;159-163.
20. Galoppin L, Noirot C, wastiaux J P, Scheinmann P, Paupe J, Burtin C. Comparison between number of basophils, blood histamine, and histamine release in cancer and noncancer patients. J Allergy Clin Immunol. 84:1989;501-506.
21. Garcia-Caballero M, Neugebauer E, Campos R, Nunez de Castro I, Vara-Thorbeck C. Increased histidine decarboxylase (HDC) activity in human colorectal cancer: results of a study on ten patients. Agents Actions. 23:1988;357-360.
22. Garcia-Caballero M, Neugebauer E, Rodriguez F, Nunez de Castro I, Vara-Thorbeck C. Histamine synthesis and content in benign and malignant breast tumours. Its effects on other host tissues. Surg Oncol. 3:1994;167-173.
23. Garcia-Caballero M, Nunez de Castro I, Kusche J, Vara-Thorbeck C. Histamine metabolism in human breast and colorectal cancer. Its effects on other host tissue. Garcia-Caballero M, Brandes L J, Hosoda S. Histamine in Normal and Cancer Cell Proliferation. 1993;273-288 Pergamon Press, Oxford.
24. Gifford R RM, Ferguson R M, Voss B V. Cimetidine reduction of tumour formation in mice. Lancet. 1(8221):1981;638-640.
25. Gifford R RM, Voss B V, Schmidtke J R, Ferguson R M. Histamine type-2 receptor antagonist immune modulation. I. Increased cell-mediated cytotoxicity in normal and down-regulated systems. Surgery. 103:1988;184-192.
26. Hallissey M T, Dunn J A, Baker P G, Davis J G, Billingham L J. A prospective randomised trial of cimetidine therapy in gastric cancer: An interim report (abstract). Gut. 39 (Suppl. 1):1996;W47.
27. Hershkoviz R, Lider O, Baram D, Reshef T, Miron S, Mekori Y A. Inhibition of T cell adhesion to extracellular matrix glycoproteins by histamine: a role for mast cell degranulation products. J Leukocyte Biol. 56:1994;495-501.
28. Jass J R. Lymphocytic infiltration and survival in rectal cancer. J Clin Pathol. 39:1986;585-589.
29. Kelly M D, King J, Cherian M, Dwerryhouse S J, Finlay I G, Adams W J, King D W, Lubowski D Z, Morris D L. Randomized trial of preoperative cimetidine in patients with colorectal carcinoma with quantitative assessment of tumor-associated lymphocytes. Cancer. 85:1999;1658-1663.
30. Kikuchi Y, Oomori K, Kizawa I, Kato K. Effects of cimetidine on tumour growth and immune function in nude mice bearing human ovarian carcinoma. J Nat Cancer Inst. 74:1985;495-498.
31. J, King, J, RM, Caplehorn, J, K, Seifert, A, P, Preketes, P, R, Clingan, D, L, Morris.
32. Lawson J A, Adams W J, Morris D L. Ranitidine and cimetidine differ in their in vitro and in vivo effects on human colonic cancer growth. Br J Cancer. 73:1996;872-876.
33. Matsumoto S. Cimetidine and survival with colorectal cancer [Letter]. Lancet. 346:1995;115.
34. Moriarty C M, Stucky J L, Hamburger K W, Patil K D, Foley J F, Koefoot R R. Blood histamine and solid malignant tumors. J Cancer Res Clin Oncol. 114:1988;588-592.
35. Nielsen H J, Hammer J H, Gronvall S, Monrad H, Grindsted J, Nielsen H, Larsen T, Moesgaard F, Kehlet H. The effect of ranitidine on immune function, tumor response and survival in patients with liver metastases from colorectal cancer. GI Cancer. 1:1996;183-190.
36. Nielsen H J, McArdle C S, Moesgaard F, Group T RS. The effect of ranitidine on long-term survival in primary colorectal cancer: A 40 month interim analysis. GI Cancer. 2:1998;227-233.
37. Osband M E, Shen Y-J, Shlesinger M, Brown A, Hamilton D, Cohen E, Lavin P, McCaffrey R. Successful tumour immunotherapy with cimetidine in mice. Lancet. 1(8221):1981;636-638.
38. Primrose J N, Miller G V, Preston S R, Gokhale J, Ambrose N S, Ward U M, Mills J G, Ehsanullah R SB, Darekar B, Group Y GT. A prospective randomised controlled study of the use of ranitidine in patients with gastric cancer. Gut. 42:1998;17-19.
39. Reynolds J L, Akhter J A, Adams W J, Morris D L. Histamine content in colorectal cancer. Are there sufficient levels of histamine to affect lymphocyte function. Eur J Surg Oncol. 23:1997;224-227.
40. Reynolds J L, Akhter J A, Magarey C J, Schwartz P, Adams W J, Morris D L. Histamine in human breast cancer. Br J Surg. 85:1998;538-541.
41. Svendsen L B, Ross C, Knigge U, Frederiksen H J, Graversen P, Kjaergard J, Luke M, Stimpel H, Sparso B H. Cimetidine as an adjuvant treatment in colorectal cancer. Dis Colon Rectum. 38:1995;514-518.
42. Tasaka K, Kurokawa K, Nakayama Y, Kakimoto M. Effect of histamine on delayed-type hypersensitivity in mice. Immunopharmacology. 12:1986;69-77.
43. Tonnesen H, Bulow S, Fisherman K, Hjortrup A, Pedersen V M, Svendsen L B, Knigge U, Damm P, Hesselfeld P, Pedersen I K, Siemssen O J, Christiansen P M. Effect of cimetidine on survival after gastric cancer. Lancet. 2(8618):1988;990-992.
44. Tutton P JM, Barkla D H. Comparison of the tumor inhibiting effects of three histamine H2-receptor antagonists. Anticancer Res. 3:1983;7-10.
45. Watson S A, Wilkinson L J, Robertson J FR, Hardcastle J D. Effect of histamine on the growth of human gastrointestinal tumours: reversal by cimetidine. Gut. 34:1993;1091-1096.
46. 2receptors on human melanoma cells. Biochem Biophys Res Commun. 151:1988;518-523.
47. Woolley D E, Eckley D, Tetlow L C, Whitehead R J. Effect of mast cell products and histamine on the proliferative behaviour of human melanoma and carcinoma cells in vitro. Agents Actions. 38:1993;C182-C184.
48. Wotherspoon H A, Anderson J R, Morran C G, Murray G D, McArdle C S. Randomized controlled trial of an H2-receptor in gastric cancer. Br J Surg. 84:1997;1168-1169.